S-23 SARM – 20MG/ML – 30ML/60ML BOTTLE

S23 is an orally available selective androgen receptor modulator or SARM. Originally developed by GTX as a form of hormonal male contraception in rats,it exhibits a high affinity for the androgen receptor with a  K_i of 1.7 nM. Researchers, Jones et. Al published a research study comparing the effectiveness of S-23 in both castrated and intact male rats.

S-23 SARM Effects on Fertility  

In castrated male rats, the effective dose of S23 in the prostate was 0.43 mg/d and 0.079 mg/d in the levator ani muscle. In intact male rats, doses greater than 0.1 mg/d of S-23 suppressed levels of luteinizing hormone (LH) by more than 50%. Furthermore, this dose of S-23 corresponded with decreased size of the prostate and increased size of the levator ani muscle (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2630904/).

In intact males treated with S-23 as well as estradiol benzoate (to maintain sexual behavior), after 10 weeks there was no sperm found in the testis in four out of the six subjects and no reported pregnancies in all six of the subjects. After the treatment, infertility was completely reversed and 100% of the mating trials resulted in pregnancy.

S-23 SARM Effects on Muscle Mass and Body Fat

The effects of S23 on muscle mass and body fat are comparable to the effects of anabolic steroids. In a study conducted in male rats it was discovered that while being treated with S23, the overall body weight and fat mass of the rats decreased.

As it was previously mentioned, rats being treated with S23 were also given estradiol benzoate (EB) to maintain sexual behavior. EB is considered an estrogen which is known to cause muscle loss, however, when combined with S23 the effects of the estrogen were canceled out and the muscle mass of the male rats increased (https://drugs.selfdecode.com/blog/s23/).

Additionally, in another study using rats, the effectiveness of S23 was tested against muscle loss due to long-term usage of glucocorticoids. This study also looked into the effects of S23 on castration-induced atrophy. In both cases, there was muscle loss but by supplementing S23 and testosterone to the rats the dexamethasone-induced dephosphorylation of Akt is blocked. Overall this study indicated that using S23 may be a more effective way of treating glucocorticoid-induced muscle loss (https://pubmed.ncbi.nlm.nih.gov/20534726/).

Our compounds are available in powdered, poly-cell, and standard polyethylene glycol formulations.  We employ an FDA-approved amphiphilic copolymer + coconut MCT oil to form polymeric micelles that enhance the bioavailability of select SARMs.

Furthermore, our nano-emulsification process ensures minimum polymeric micelle size and variance. Most importantly, our Poly-Cell Formula TM is optimized for sublingual absorption with a minimal taste profile. This stands in contrast to PEG, which is often intolerable for sublingual delivery due to its very unpleasant taste, leading to poor compliance among research participants. However, we do offer PEG for researchers who prefer the standard research delivery method.

The primary concern for SARM researchers today is product purity.  Umbrella Labs insures and guarantees its product purity by incorporating a process of Independent testing using Mass Spectrometry and Ultraviolet Radiation. Certificates of our product Independent tests are posted with our product descriptions.

**LAB USE ONLY**

*This information is for educational purposes only and does not constitute medical advice. THE PRODUCTS DESCRIBED HEREIN ARE FOR RESEARCH USE ONLY. All clinical research must be conducted with oversight from the appropriate Institutional Review Board (IRB). All preclinical research must be conducted with oversight from the appropriate Institutional Animal Care and Use Committee (IACUC) following the guidelines of the Animal Welfare Act (AWA).